Breakthrough medication significantly cuts risk of heart attacks and strokes: Lancet study
A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...
Science Daily6h
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Healio11h
Few hospitalized adults with type 2 diabetes prescribed SGLT2, GLP-1 medication
Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...
Lexicon’s sotagliflozin shows cardiovascular efficacy in published study
Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...
Medindia18h
New Anti-Diabetic Drug Sotagliflozin Reduces Heart Disease and Stroke Risks
Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...